Capricor Therapeutics Announces Intent to File Biologics License ...
WEB15 hours ago · More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the ...
Capricor Therapeutics Shares Rise in Premarket on Plans to File ...
WEB13 hours ago · Capricor said that the data in the filing will be based on existing cardiac data from its phase 2 trials. ... Dow Jones Newswires is a market-moving financial and business news source, used by ...
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
WEB1 day ago · MGNX. Capricor Therapeutics (CAPR) shares rallied 18.2% in the last trading session to close at $5.97. This move can be attributable to notable volume with a higher number of shares being traded ...
Capricor Therapeutics Announces Intent to File Biologics License ...
WEB1 day ago · Webcast Details. Capricor will host a conference call and webcast at 8:30 a.m. ET today to discuss these updates. To participate in the conference call, please dial 1-800-717-1738 (domestic/toll ...
Capricor stock surges on pipeline update (NASDAQ:CAPR)
WEB12 hours ago · Shares of Capricor Therapeutics (NASDAQ: CAPR) surged in the morning hours on Tuesday after the cell therapy developer announced plans to seek FDA approval for its lead candidate deramiocel (CAP ...
Capricor surges on plans to seek FDA approval for lead asset - MSN
WEBS hares of Capricor Therapeutics (NASDAQ: CAPR) surged in the morning hours on Tuesday after the cell therapy developer announced plans to seek FDA approval for its lead candidate deramiocel (CAP ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
WEBJul 1, 2024 · Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway.
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 ...
WEBSAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate upd...
Why Capricor Therapeutics Stock Is Soaring Tuesday
WEB13 hours ago · CAPR Price Action: Capricor shares were up 27.1% at $7.63 at the time of publication, according to Benzinga Pro. Photo: 3844328 from Pixabay. Market News and Data brought to you by Benzinga APIs
News & Events :: Capricor Therapeutics, Inc. (CAPR)
WEBJun 6, 2024 · Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update.